Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03ISJ
|
|||
| Former ID |
DNC002387
|
|||
| Drug Name |
BMS-863233
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1/2 | [1], [2] | |
| Company |
Bristol Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12ClN3O2
|
|||
| Canonical SMILES |
C1CC(NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl
|
|||
| InChI |
1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m0/s1
|
|||
| InChIKey |
JJWLXRKVUJDJKG-VIFPVBQESA-N
|
|||
| CAS Number |
CAS 1169558-38-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CDC7-related kinase (CDC7) | Target Info | Modulator | [3], [4] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8113). | |||
| REF 2 | ClinicalTrials.gov (NCT00838890) A Study of BMS-863233 in Patients With Hematologic Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. | |||
| REF 4 | The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.PLoS One.2014 Nov 20;9(11):e113300. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.